Business
Helix BioPharma Reports On 2009 Annual General Meeting
Helix BioPharma Reports On 2009 Annual General Meeting
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nDec. 9, 2009 (Canada NewsWire Group) -- AURORA, Ontario, Dec. 9 /CNW/ --Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) reports that at its Annual General Meeting held today, shareholders approved all of management's proposals.Board of DirectorsAll seven Board members were re-elected as directors, with the Board continuing to be constituted of: Donald H. Segal, Chairman of the Board and Chief Executive Officer Kenneth A. Cawkell, Director and Corporate Secretary John Docherty Director, President and Chief Operating Officer Thomas Hodgson, Director Jack Kay, Director Gordon M. Lickrish, Director Kazimierz Roszkowski-Sliz, DirectorAuditorKPMG LLP was re-appointed as the Company's auditor.By-Law No. 1 (2009)The shareholders approved the repeal of former By-Law No. 1 and the adoption of new By-law No. 1 (2009) of the Company. By-law No. 1 (2009) as approved is being filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.shtml.Corporate PresentationThe slide show portion of the corporate presentation given at the meeting has been posted on the Company's website at www.helixbiopharma.com.About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol \"HBP\" and on the OTCQX International Market under the symbol \"HXBPF\". For further information contact: Investor Relations Robert Flamm, Ph.D. Russo Partners LLC Tel: (212) 845-4226 Email: [email protected] www.russopartnersllc.com Media Relations Ian Stone Russo Partners LLC Tel: (619) 528-2220 Email: [email protected] News Release contains certain forward-looking statements and information (collectively, \"forward-looking statements\") regarding the development of products by Helix for the prevention and treatment of cancer based on its proprietary technologies, which assumes, among other things, their ultimate successful commercialization. Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of nume...